Norwich Pharmaceuticals, Inc. v. Xavier Becerra, et al
| Norwich Pharmaceuticals, Inc. |
| Xavier Becerra, in his official capacity as Secretary of Health and Human Services, Robert McKinnon Califf, M.D., in his official capacity as Commissioner of Food and Drugs and United States Food and Drug Administration |
| Salix Pharmaceuticals, Inc. |
| 23-5311 |
| December 29, 2023 |
| U.S. Court of Appeals, D.C. Circuit |
| Other Statutes APA/Review Agency |
Docket Report
RSS Track this Docket
This docket was last retrieved on February 2, 2024. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| CLERK'S ORDER [2038557] filed granting motion to hold case in abeyance [ # 2038395-2 ]. Case 23-5311 held in abeyance pending decision in 22-2153, 23-1952 from U.S. Court of Appeals for the Federal Circuit. Motions to govern further proceedings due 30 days of court's disposition of case; directing parties to file abeyance status report due by 03/04/2024 [23-5311] [Entered: 02/02/2024 09:26 AM] |
| TRANSCRIPT STATUS REPORT [2038380] filed by Norwich Pharmaceuticals, Inc. [Service Date: 02/01/2024 ]. Status of Transcripts: Final - All transcripts needed for the appeal have been completed and received. [23-5311] (Landmon, Chad) [Entered: 02/01/2024 11:13 AM] |
| STATEMENT OF INTENT REGARDING APPENDIX DEFERRAL [2038377] filed by Norwich Pharmaceuticals, Inc. [Service Date: 02/01/2024 ] Intent: AppxDeferred [23-5311]--[Edited 02/01/2024 by LMM] (Landmon, Chad) [Entered: 02/01/2024 11:11 AM] |
| UNOPPOSED MOTION [2038395] to hold case in abeyance filed by Norwich Pharmaceuticals, Inc. [Service Date: 02/01/2024 ] Length Certification: The foregoing motion brief is in 14-Point Times New Roman proportional font and contains 717 words and thus in compliance with the type-volume limitation set forth in D.C. Circuit Rule 27(d)(2)(A).. [23-5311] (Landmon, Chad) [Entered: 02/01/2024 11:50 AM] |
| CERTIFICATE AS TO PARTIES, RULINGS AND RELATED CASES [2038444] filed by Salix Pharmaceuticals, Inc. [Service Date: 02/01/2024 ] [23-5311] (Salmons, David) [Entered: 02/01/2024 02:12 PM] |
| STATEMENT [2038521] with Disclosure Listing filed by Salix Pharmaceuticals, Inc. [Service Date: 02/01/2024 ] [23-5311] (Salmons, David) [Entered: 02/01/2024 05:10 PM] |
| UNDERLYING DECISION IN CASE [2038373] submitted by Norwich Pharmaceuticals, Inc. [Service Date: 02/01/2024 ] [23-5311] (Landmon, Chad) [Entered: 02/01/2024 11:10 AM] |
| ENTRY OF APPEARANCE [2038439] filed by David B. Salmons and co-counsel William R. Peterson; Amanda L. Salz on behalf of Appellee Salix Pharmaceuticals, Inc.. [23-5311] (Salmons, David) [Entered: 02/01/2024 02:09 PM] |
| STATEMENT OF ISSUES [2038371] filed by Norwich Pharmaceuticals, Inc. [Service Date: 02/01/2024 ] [23-5311] (Landmon, Chad) [Entered: 02/01/2024 11:04 AM] |
| DOCKETING STATEMENT [2038368] filed by Norwich Pharmaceuticals, Inc. [Service Date: 02/01/2024 ] [23-5311] (Landmon, Chad) [Entered: 02/01/2024 11:02 AM] |
| ENTRY OF APPEARANCE [2038366] filed by Chad A. Landmon on behalf of Appellant Norwich Pharmaceuticals, Inc.. [23-5311] (Landmon, Chad) [Entered: 02/01/2024 11:00 AM] |
| CERTIFICATE AS TO PARTIES, RULINGS AND RELATED CASES [2038369] filed by Norwich Pharmaceuticals, Inc. [Service Date: 02/01/2024 ] [23-5311] (Landmon, Chad) [Entered: 02/01/2024 11:03 AM] |
| ENTRY OF APPEARANCE [2035443] filed by Joshua Dos Santos and co-counsel Daniel Tenny on behalf of Appellees Xavier Becerra, Robert McKinnon Califf, M.D. and FDA. [23-5311] (Dos Santos, Joshua) [Entered: 01/11/2024 05:35 PM] |
| CERTIFICATE AS TO PARTIES, RULINGS AND RELATED CASES [2035444] filed by Xavier Becerra, Robert McKinnon Califf, M.D. and FDA [Service Date: 01/11/2024 ] [23-5311] (Dos Santos, Joshua) [Entered: 01/11/2024 05:42 PM] |
| CLERK'S ORDER [2034017] filed directing party to file initial submissions: APPELLANT docketing statement due 02/01/2024. APPELLANT certificate as to parties due 02/01/2024. APPELLANT statement of issues due 02/01/2024. APPELLANT underlying decision due 02/01/2024. APPELLANT deferred appendix statement due 02/01/2024. APPELLANT entry of appearance due 02/01/2024. APPELLANT transcript status report due 02/01/2024. APPELLANT procedural motions due 02/01/2024. APPELLANT dispositive motions due 02/16/2024; directing party to file initial submissions: APPELLEE certificate as to parties due 02/01/2024. APPELLEE entry of appearance due 02/01/2024. APPELLEE procedural motions due 02/01/2024. APPELLEE dispositive motions due 02/16/2024 [23-5311] [Entered: 01/02/2024 02:45 PM] |
| NOTICE OF APPEAL [2034010] seeking review of a decision by the U.S. District Court in 1:23-cv-01611-RDM filed by Norwich Pharmaceuticals, Inc.. Appeal assigned USCA Case Number: 23-5311. [23-5311] [Entered: 01/02/2024 02:32 PM] |
| US CIVIL CASE docketed. [23-5311] [Entered: 01/02/2024 02:31 PM] |
Access additional case information on PACER
Access the Case Summary and Docket Report to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
